Where Will Novo Nordisk Stock Be in 3 Years?
Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.
Overview
Novo Nordisk (NYSE: NVO) fell by 29% over the last 12 months, and that's making investors antsy about the company's next three years. It's clear that it won't be able to coast on its earnings from sales of Ozempic.
Let's chart out Novo's path over the next three years to see where its stock will be, given that investors have been dumping it recently.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.